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The modern era of whole organ transplantation 
began in 1962, when drugs were used in combina-
tion to treat patients after the technically easy 
operation of kidney transplantation. The simple 
kidney model continued for a long time to be the 
front-runner for advances in the four key ele-
ments of clinical transplantation, which could 
then be applied with minor adaptations for the 
extrarenal organs. The elements are (1) preser-
vation, (2) tissue matching, (3) immunosuppres-
sion, and (4) surgical technique. This orderly pro-
gression changed within the last 10 years when 
the liver emerged as a focal organ of scientific 
inquiry. 
For example, the liver has been central in test-
ing better techniques of "slush" preservation. 
Such methods were introduced more than two 
decades ago, using a potassium-rich electrolyte 
solution or a plasmalike solution to cool kidneys 
by intra-arterial infusion, followed by refrigera-
tion in an ice chest. Cadaveric kidneys could be 
cooled in this way for 24 to 48 hours, but the 
safety limit for livers treated in the same way was 
only 6 to 10 hours. Using a different electrolyte 
solution, hearts could be stored for a maximum of 
6 hours. 
A new preservative solution developed at the 
University of Wisconsin is in the process of ex-
panding all of these outer limits. The University 
of Wisconsin solution was originally designed for 
preservation of the pancreas, 1 but after verifying 
its preservative powers in canine liver experi-
ments; full-scale clinical trials for hepatic trans-
plantation followed, with revolutionary results. 3,4 
The ability to store human livers for a day instead 
of a few hours allowed improvements at every 
level of what previously had been an exercise 
in urgency and administrative inconvenience. 
The University of Wisconsin solution protects 
the microvasculature of the transplanted whole 
organ, among other effects, and therefore should 
be beneficial for storing all organs, including the 
kidney and heart. Several experimental studies 
have already confirmed this expectation. 
With the kidney and perhaps the heart, good 
tissue matching of a recipient with a cadaveric 
donor can confer a small but significant advan-
tage. A paradox has been reported from two 
large centers that found the outcome after liver 
transplantation to be actually degraded by good 
matching. 5,6 This has been explained by an "MHC 
(major histocompatibility complex) restriction" 
hypothesis, which holds that factors that de-
stroyed the native liver are apt to damage the 
homograft in proportion to the quality of the 
HLAmatch. 
A nother curiosity in hepatic transplantation 
is the ability of the liver to resist destruction by 
the preformed cytotoxic antigraft antibodies that 
can immediately destroy kidney and heart grafts 
in a process called "hyperacute rejection." This 
has meant that the conventional cytotoxic cross-
match is irrelevant in pairing liver donors and 
their hepatic recipients.' Why the liver is ex-
cluded from a risk common to other organs has 
not been answered. One groupS has shown that 
livers immediately produce soluble HLA anti-
gens in quantities large enough to allow HLA 
typing in the plasma. Such antigens conceivably 
could neutralize antibodies or contribute to toler-
ance induction. 
Nevertheless, there is mounting evidence that 
livers can be destroyed quickly by perioperative 
immune events that are not necessarily associ-
ated with cytotoxic antibodies. 9 When this oc-
curs, a second liver transplant has a much higher 
than normal probability of prompt destruction 
(primary nonfunction). Such recipients have been 
referred to as "liver eaters."· Finding why some 
patients provide such a hostile environment for 
livers even when antigraft antibodies may be ab-
sent could explain why a significant number of 
kidneys and hearts are still being lost to hyper-
acute rejection, despite the most discriminating 
immunologic screening available today. 
The revolution in clinical transplantation since 
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1979 would not have been possible without cyclo-
sporine, an agent that allowed greater control of 
rejection with less toxicity than previously possi-
ble. Cyclosporine is used with other agents, of 
which prednisone is the most important, but also 
including azathioprine and the antilymphocyte 
globulin agents. Polyclonal antilymphocyte glob-
ulin has been replaced increasingly with mono-
clonal preparations that range in target specific-
ity from all mature lymphocytes (OKT3) to 
interleukin 2 receptors. 
The principal limitation of cyclosporine is its 
nephrotoxicity, which imposes dose ceilings and 
which may cause kidney lesions that are irrevers-
ible. This latter possibility has been particularly 
well studied in heart recipients. '0 The nephrotoxi-
city has not been completely eliminated by com-
plex mUltiple-drug regimens in which low doses of 
the constituent drugs, including cyclosporine, 
are given. This impasse has stimulated a search 
for new agents. 
The most promising new drug is FK 506, which 
is produced by a bacterium, Streptomyces tsuku-
baensis. FK 506 was discovered in 1984 and first 
described in the literature in 1987." FK 506 has 
been studied exhaustively in rats, dogs, and ba-
boons and is nearing clinical trials. It acts primar-
ily by inhibiting interleukin 2 synthesis and bind-
ing in the same way as cyclosporine, with which it 
is synergistic. '2 It is relatively nontoxic in rats 
and subhuman primates, but has significant gas-
trointestinal toxicity in dogs. Nephrotoxicity has 
not been seen in animals, but neither was nephro-
toxicity observed in animals treated with 
cyclosporine. 
Various organ combinations have been trans-
planted, including the pancreas plus kidney or 
liver; heart and kidney; heart and liver; and 
heart-lung plus liver. Conventional operations 
were performed one after the other in each pa-
tient, under the same anesthesia and using the 
same donor. The use of multivisceral grafts (or-
gan clusters) without first separating them has 
added a new dimension. In the most extensive 
such procedure, all of the intra-abdominal viscera 
were replaced, including the gastrointestinal 
tract from the stomach to the colon. 13 The maxi-
mum survival with this operation has been 6 
months. Transplantation of smaller clusters has 
allowed removal of the stomach, liver, pancreas, 
duodenum, spleen, proximal jejunum, and most 
of the colon in treating malignancies involving the 
liver plus pancreas, duodenum, or colon. '4 The 
void in the upper abdomen has been filled with 
organ cluster grafts that contain at the minimum 
the liver, pancreas, and duodenum. 
At least 16 inborn errors of metabolism are 
known to have been treated with liver transplan-
tation.'· In some of these diseases, the inborn 
error had been responsible for damage to the liver 
with resulting cirrhosis and/or malignant degen-
eration. Correction of the inborn error by trans-
plantation in these patients was incidental. 
Recently, liver replacements have been carried 
out solely for the correction of inborn errors, 
removing and replacing a liver that was anatom-
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ically normal. Examples include familial hy-
percholesterolemia, primary oxalosis, Crigler-
Najjar syndrome (glucuronyl transferase defi-
ciency), and protein C deficiency. In some dis-
eases in which the pathogenesis of the inborn 
error was imperfectly understood, study of these 
patients provided important clues or even defini-
tive answers about the true nature of the 
disorder. 
The cap for transplantation of any of the vital 
organs will be imposed by organ availability. Be-
cause of this, the criteria for donor candidacy are 
being reexamined. The number of available 
hearts and livers would be increased greatly by 
removing arbitrary upper age limits (usually 45 
or 50 years) for donorship, as already has been 
done with kidney donors. Donors by the hun-
dreds or perhaps thousands are undoubtedly be-
ing rejected because of rules or guidelines that 
are obsolete or inflexible. The cardiodynamic sta-
bility that was once a criterion of donor suitability 
may also be an unjustifiable requirement. It has 
been well documented in the United States and in 
a European study that so-called nonideal donors 
with unstable blood pressure, poor blood gas val-
ues, or even abnormal results on liver or kidney 
function tests can provide good organs. 
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